CPACS: Research, Results, Market Comparisons, and Valuations, page-222

I have just seen something that is very important for holders to know.

Given that ROS production universally contributes to cardiotoxicity in anti-cancer drugs used alongside Bisantrene, and early preclinical data clearly demonstrate that Bisantrene reduces ROS production in the cytoplasm and mitochondria of cardiomyocytes, I believe it’s reasonable to conclude that Bisantrene has a direct impact on ROS production in heart cells.




Something that has been dangling right infront of us for a while now is the effect Bisantrene has on ROS production in cancerous cells. For heart cells and cancer cells alike, ROS production is very damaging. My concern has been that Bisantrene’s cardioprotective properties might reduce its effectiveness in targeting cancer, which is where its real value lies. However, the preclinical study from MD Anderson, which looked at Bisantrene both as a single agent and in combination with other hematological therapies, has explored its effects on ROS production in cancer cells.



It's hard to believe, but the image on the bottom is from a 2021 study, while the above images are from the 1980s, hah.

Here is what I think the key takeaways are from this data:
1. Bisantrene decreases ROS production in cardiomyocytes
- Evidenced by the 1-fold reduction and complete elimination of ROS molecules
2. Bisantrene increases ROS production in cancer cells
- Evidenced by the 2-fold and ~1.3-fold increase in ROS molecules

This could be an early indication that Bisantrene's cardioprotective mechanism is unique to certain cell types and that its specific target operates in a particular way within those cells. It also suggests that this cardioprotective effect may not interfere with Bisantrene’s anti-cancer activity, even when combined with other drugs, through its modulation of ROS production.

I need more data @RaceOncology